Results 311 to 320 of about 115,987 (377)

Use of dipeptidyl peptidase-4 inhibitors is associated with lower risk of severe renal outcomes in pre-dialysis patients with Type 2 diabetes. [PDF]

J Intern Med
Hung TY, Lin TC, Liou YJ, Lin TH, Hsu YJ, Lin LY, Wang MT.   +6 more
europepmc   +1 more source

Dipeptidyl peptidase-4 enzyme inhibition and its impacts on hepatic preneoplasia: a new avenue for liver cancer management. [PDF]

Front Pharmacol
Eitah HE, Sayed RH, Maklad YA, Gamal El Din AA, Mahmoud K, El-Sahar AE, Alhejely A, Abdulbaqi AA, Naeim Attia H.   +8 more
europepmc   +1 more source

PARP inhibitor-induced anti-tumour chemokine response is suppressed by dipeptidyl peptidase 4 (DPP4) in ovarian cancer. [PDF]

Br J Cancer
Stange C, Dreyer TF, Riedel M, Elsen F, Seitz S, Hamann D, Kiechle M, Bronger H.   +7 more
europepmc   +1 more source

Comparison of the Efficacy of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter-2 Inhibitors in Diabetic Patients with Steatotic Liver Disease. [PDF]

Gut Liver
Ko Y, Hur MH, Park Y, Park J, Shin H, Lee YB, Cho EJ, Lee JH, Yu SJ, Yoon JH, Kim YJ.   +10 more
europepmc   +1 more source

Association of Dipeptidyl Peptidase-4 Inhibitors with Glaucoma Risk in Patients with Type 2 Diabetes: A Nationwide Cohort Study. [PDF]

Ophthalmol Sci
Lu YA, Tien PT, Cheng YD, Hsieh YW, Cho DY, Tsai SF, Weng CH, Lin HJ, Lin HJ, Wang IJ, Chou CC.   +10 more
europepmc   +1 more source

Effect of Beta-Cell Function on Glucose Variability When Switching From Insulin Degludec Plus a Dipeptidyl Peptidase-4 Inhibitor to Insulin Degludec/Liraglutide: Preliminary Results From a Pilot Study. [PDF]

Int J Endocrinol
Oe Y, Nomoto H, Nakamura A, Kuwabara S, Takahashi Y, Yasui A, Izumihara R, Miya A, Kameda H, Cho KY, Atsumi T.   +10 more
europepmc   +1 more source

Dipeptidyl peptidase 4 as an injury-responsive protein in the mouse sciatic nerve. [PDF]

Mol Cells
Oh Y, Cho Y.
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus

Nature Reviews Endocrinology, 2020
Carolyn F Deacon
exaly   +2 more sources

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

Lancet, The, 2006
Michael A Nauck
exaly   +2 more sources